# Sermorelin Research: GH/IGF-1 Findings, Mechanism, and Side Effects > Sermorelin research summarized: the GHRH(1-29) mechanism, pediatric and aging GH/IGF-1 trials, the GHRH-analog cognition data, and reported side effects. Every claim cited to source. Mechanism, the human GH/IGF-1 record, the GHRH-analog cognition and body-fat data, and the reported safety profile — each finding filed to its study. ## The short version This page collects the sermorelin research in one place. The headline facts: GHRH(1-29) sped up growth in growth-hormone-deficient children [1]; it nudged growth hormone and IGF-1 (the liver's growth signal) back toward youthful levels in older men over two weeks [2]; and a closely related, longer-acting version of the molecule was linked to better thinking scores and less body fat in older adults over 20 weeks [6]. Reported side effects in trials are generally mild. The honest limit: long-term "anti-aging" use in adults is not proven, and authorities have said so plainly [5]. ## Sermorelin Mechanism of Action Sermorelin is the 1-29 N-terminal fragment of GHRH and the shortest fragment that retains full GHRH activity [15]. It binds the GHRH receptor — a class B G-protein-coupled receptor — on pituitary somatotrophs and activates Gs / adenylate cyclase / cAMP / protein kinase A signaling, raising GH gene transcription and triggering pulsatile GH release; GH in turn drives hepatic IGF-1 [15]. The mechanistic advantage is preserved feedback: somatostatin (the inhibitory brake on the somatotroph) and IGF-1 continue to regulate the axis, so secretion stays pulsatile rather than flat [4]. Receptor activation also exerts a trophic effect on somatotrophs, which distinguishes a secretagogue's action from a one-time stimulus [15]. A 2025 Nature Reviews Endocrinology review by Granata and colleagues is the current reference frame for where GHRH(1-29) sits among GHRH agonists and antagonists, synthesizing receptor signaling, the GH/IGF-1 axis, and the therapeutic landscape across health and disease [15]. ## The human GH and IGF-1 record The most direct adult evidence comes from healthy older men (mean 68 years): subcutaneous GHRH(1-29) at 0.5 mg and 1 mg twice daily for 14 days produced dose-related increases in 24-hour GH and IGF-1, and after high-dose treatment GH/IGF-1 parameters no longer differed from those of young men, with no effect on fasting glucose [2]. That last detail matters — it is direct evidence that the rise came through the body's own regulated axis rather than by overriding it. In healthy men, intravenous GHRH(1-29)NH2 elicited GH release at doses as low as 0.25 mcg/kg, with maximal release at 1-2 mcg/kg; despite rapid elimination, GH remained elevated for about 3 hours [3]. The dose-response holds across routes: the analog [Nle27]GHRH(1-29)-NH2 stimulated GH dose-responsively by intravenous, subcutaneous, and intranasal administration without adverse effect, requiring roughly tenfold higher subcutaneous and thirtyfold higher intranasal doses than intravenous to achieve comparable release [14]. Single nightly GHRH(1-29) injections in healthy elderly men were studied specifically for nocturnal GH/IGF-1 output, probing whether bedtime dosing restores the overnight pulse that fades with age [12]. The earliest of this adult work — the pediatric efficacy trial — remains the cleanest demonstration of a real-world endpoint: first-year height velocity rose from about 4.1 cm/year to roughly 7-8 cm/year in GH-deficient children, without excessive IGF-1 generation [1]. ## From diagnostic tool to research peptide Before it was studied for aging, GHRH(1-29) had a diagnostic life. Because a GHRH signal reliably provokes the pituitary to release GH, a single intravenous dose served as a GH stimulation test — a way to probe the pituitary's capacity to secrete growth hormone [3]. The dose-response work that underpins that use is well characterized: GH release scaled with dose from as low as 0.25 mcg/kg up to a maximum at 1-2 mcg/kg in healthy men [3], and the [Nle27] analog confirmed the same dose-responsive behavior across three routes of administration [14]. That diagnostic reliability is the same property — a predictable, feedback-regulated GH pulse — that later made the molecule interesting as a research probe of the aging GH/IGF-1 axis. The continuity is worth noticing: the pharmacology that made it a clean test is the pharmacology the adult-axis research is built on. ## GHRH-axis cognition and the SMART trial A randomized, placebo-controlled trial of a daily subcutaneous GHRH analog (tesamorelin, 1 mg/day before bedtime) in 152 older adults — 66 with mild cognitive impairment — found a favorable effect on cognition (P=0.03; executive function P=0.005) over 20 weeks, increased IGF-1 by 117% within the physiologic range, reduced percent body fat by 7.4%, and reported mild adverse events (NCT00257712, the SMART trial) [6]. Two cautions belong with that result. First, it is for the stabilized analog, not GHRH(1-29) itself; it is presented here among the strongest [GHRH-axis cognition trials](/research) in the literature, not as proof of a sermorelin cognition indication. Second, the IGF-1 rise stayed within the physiologic range rather than pushing past it, consistent with the feedback-preserving mechanism of the whole class. The metabolic edge of the axis is also documented: a GHRH analog altered endogenous GH pulsatility and insulin sensitivity in healthy men, showing that GHRH-axis stimulation can modulate both GH secretory dynamics and glucose handling [13]. Taken together, the adult GHRH-analog literature is consistent — measurable GH/IGF-1 and body-composition effects in defined populations — while stopping well short of a proven general anti-aging indication. ## Sermorelin vs Ipamorelin: GHRH vs Ghrelin-Receptor Secretagogues Sermorelin and ipamorelin both raise GH, but through different receptors. Sermorelin is a GHRH analog acting at the GHRH receptor; ipamorelin is a growth-hormone-releasing peptide (GHRP) acting at the ghrelin/GHS receptor [15]. The two mechanisms are complementary — GHRH analogs and GHRPs are sometimes studied together because they stimulate the somatotroph by separate pathways. The practical distinction for the literature is that sermorelin's evidence base sits within the GHRH-analog family (and its stabilized relatives), whereas the GHRP class is a different pharmacology with its own dataset [15]. ## Sermorelin Side Effects Reported in Studies Reported effects in trials are generally mild — injection-site reactions are the most common, and adverse events in the GHRH-analog SMART trial were characterized as mild [6]. The pediatric efficacy trial reported acceleration of growth without excessive IGF-1 generation [1], and the 14-day older-men study found no effect on fasting glucose [2]. The principal caution is theoretical rather than observed: because GH and IGF-1 are mitogenic (they promote cell division), chronically raising them is theorized to carry oncologic risk, a recognized consideration for any GH-axis intervention — even one that works through the body's own feedback-regulated pulsatile secretion. On the broader question of anti-aging use, an Annals of Internal Medicine editorial cautioned that GH-secretagogue use to prevent or treat aging is not yet justified by the evidence [5]. ## How the adult evidence should and should not be read Two reading errors recur with the sermorelin literature, and both are worth naming. The first is inheriting tesamorelin's results: the body-composition and cognition signals carried by the stabilized analog [6][7][9] are frequently restated as sermorelin findings, when the molecule actually studied was its longer-acting relative. The second is single-finding extrapolation — treating a striking result in one narrow setting as if it generalized into a broad indication. The disciplined reading is the one this page tries to hold: GHRH(1-29) reliably raises GH and IGF-1 in defined populations [2], its pharmacokinetics are well characterized [3], its drug class shows real body-composition effects in specific clinical groups [7][9], and the long-term adult anti-aging case remains unestablished [5]. Each of those statements is true at once; none cancels the others. A further practical note for athletes and researchers: growth-hormone secretagogues, including GHRH analogs, are prohibited in sport by WADA, and dedicated detection methods have been developed. That is a regulatory fact about the class, separate from the efficacy and safety questions above. --- The sermorelin record filed cell by cell on a research board — every GH and IGF-1 figure carried back to its study, the body-composition evidence marked as tesamorelin where it belongs, and the empty long-term-safety cell left openly unfilled; no clinic behind the board and nothing here dosed, dispensed, or sold.